■ Epidemiology of ovarian cancer: a review
Brett M. Reid, Jennifer B. Permuth, Thomas A. Sellers
Cancer Biol Med. 2017 Feb; 14(1): 9–32
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365187/
■ Diagnosis and management of ovarian cancer
C A Doubeni, A R B Doubeni, A E Myers
American Family Physician 2016, vol 93 (11): 937-944
http://www.aafp.org/afp/2016/0601/p937.html
■ Global trends and predictions in ovarian cancer mortality
M Malvezzi, G Carioli, T Rodriguez et AL
Annals of Oncology 2016, vol 27 (11): 2017-20125
https://academic.oup.com/annonc/article/27/11/2017/2467050
■ Sexual health, mental health, and beliefs about cancer treatments among women attending a gynecologic oncology clinic
Lisa Eaton, Angela Kueck, Jessica Maksut et al
Sex Med. 2017, vol 5(3): e175–e183
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562497/
■ Giant ovarian teratoma: an important differential diagnosis of pelvic masses in children
F N Figueiras, M L Duarte, E R Duarte et al
RadiolBras 2017, vol 50 (5): 342-343
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656080/
■ Laparoscopic staging for apparent stage I epithelial ovarian cancer
A Melamed, N L Keating, J T Clemmer et al
American Journal of Obstetrics & Gynecology 2017, vol 216 (1)
http://www.ajog.org/article/S0002-9378(16)30595-6/fulltext
■ Pathological features and clinical behavior of Lynch syndrome associated ovarian cancer
N.A.J. Ryan, D.G. Evans, K. Green, E.J. Crosbie
GynecolOncol. 2017, vol 144(3): 491–495
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345899/
■ The challenge of ovarian cancer. Steps toward early detection through advanced signal processing in magnetic resonance spectroscopy
Kelkic, D Belkic
IMAJ 2017, vol 19
https://www.ima.org.il/FilesUpload/IMAJ/0/251/125767.pdf
■ A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumors
Matthew R Russell, Ciaren Graham, Alfonsina D’Amato et al
Br J Cancer. 2017 Aug 22; 117(5): 666–674
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572165/
■ Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistancetotaxanes in ovarian câncer cells and are associated with epithelil-to-mesenchymal transition
George E Duran, Yan C Wang, François Moisan, E Brian Francisco, Branimir I Sikic
Br J Cancer. 2017 May 9; 116(10): 1318–1328
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482726/
■ The role of endocrine G protein-coupled receptors in ovarian cancer progression
Qingyu Zhang, Nadine Ellen Madden, Alice Sze Tsai Wong, Billy Kwok Chong Chow, Leo TszOn Lee
Front Endocrinol (Lausanne) 2017; 8: 66.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383648/
■ Acute Abdomen Secondary to Ruptured Epithelial Ovarian Cancer during Pregnancy: The Relevance of Teamwork
Ortiz-Mendoza, Carlos Manuel et al
Rev. Bras. Ginecol. Obstet., Sept 2017, vol.39, no.9, p.513-515
■ The cost-effectiveness of screening for ovarian cancer, results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Usha Menon, Alistair J McGuire, Maria Raikou et al
Br J Cancer.2017, vol117(5): 619–627
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572177/
■ Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer
Madhumita Chatterjee, Laura C. Hurley, Michael A. Tainsky
GynecolOncol Rep.2017, vol21: 37–44
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476453/
■ Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
TusharTomar, Nicolette G. Alkema, Leroy Schreuder et al
BMC Med.2017; vol15: 116.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481993/
■ Resolution of diffuse intrahepatic biliary strictures after chemotherapy for metastatic ovarian cancer
Daniel Lew, Vinay Sundaram, Brad D. Barrows, Simon K. Lo, Srinivas Gadda
ACG Case Rep J.2017; vol4: e77
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464395/
■ Ovarian needle aspirationg in the diagnosis and management of ovarian masses
Kimberly Nagamine, Jordan Kondo, Ricky Kaneshiro et al
J Gynecol Oncol.2017, vol28(4): e40
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447143/
■ Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer
NienkeZwakman, Rafli van de Laar, Toon Van Gorp et al
J GynecolOncol.2017, vol 28(1): e7.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165075/
■ Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelian ovarian, tubal, or peritoneal carcinoma: a propensity score-matched analysis of 112 consecutive patients
Akimasa Takahashi, Kazuyoshi Kato, Motoki Matsuura et al
Medicine (Baltimore) 2017, vol96(37): e8006
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604650/
■ Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature
Nam G, Lim YM, Cho MS, Lee J, Kim YH.
ObstetGynecol Sci. 2017 Nov;60(6):593-5
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571707/
■ Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?
DimitriosNasioudis, Eloise Chapman-Davis, Melissa K. Freyet al
J Gynecol Oncol.2017, vol28(6): e71
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641522/
■ Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates
LimorHelpman, OmriZidan, Eitan Friedman et al
J Gynecol Oncol.2017 Sep; 28(5): e61
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540720/
■ A multiplex platform for the identification of ovarian cancer biomarkers
Kristin L. M. Boylan, Kate Geschwind, Joseph S. Koopmeiners et al
Clin Proteomics. 2017; vol14: 34
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634875/
■ Ovarian cancer: density equalizing mappingof the global research architecture
DörtheBrüggmann, Katharina Pulch, Doris Klingelhöfer et al
Int J Health Geogr.2017; vol16: 3
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237222/
■ Hipercalcemia e hipofosforemiaenniñacon tumor ovárico.
UbetagoyenaArrieta, Mercedes et al.
Nefrología (Madr.), Feb 2017, vol.37, no.1, p.100-101
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952017000100100&lng=en&nrm=iso
■ Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
Rosie T. Jiang, Anna Yemelyanova, Deyin Xing et al
J Ovarian Res. 2017; 10: 53.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547474/
■ A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass
Santosh Kumar Dora, Atal Bihari Dandapat, Benudhar Pande, Jatindra Prasad Hota
J Ovarian Res. 2017; 10: 55.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556625/
■ Biological effects of combined resveratrol and vitamin D3 on ovarian tissue
Francesca Uberti, Vera Morsanuto, Silvio Aprile et AL
J Ovarian Res. 2017; 10: 61
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602920/
■ Increased`RHAMM expression relates to ovarian cancer progression
Stephanie T. Buttermore, Mitchel S. Hoffman, Ambuj Kumar et al
J Ovarian Res. 2017; 10: 66
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618727/
■ Prediction of clinical response to drugs in ovarian câncer using the chemotherapy resistance test (CTR-test)
Frank Christian Kischkel, Carina Meyer, Julia Eich et al
J Ovarian Res. 2017; 10: 72.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658930/
■ Ovarian mature cystic teratoma: challenges of surgical management
Abha Sinha, Ayman A. A. Ewies
Obstet Gynecol Int. 2016; 2016: 2390178
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823513/
■ Targeting the tumor microenvironment in ovarian cancer
Jean M. Hansen, Robert L. Coleman, Anil K. Sood
Eur J Cancer. 2016, vol 56: 131–143
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769921/
■ Ultrasound monitoring of extant adnexal masses in the era of type 1 and type 2 ovarian cancer: lessons learned from ovarian cancer screening trials
Eleanor L. Ormsby, Edward J. Pavlik, John P. McGahan
Diagnostics (Basel) 2016, vol7(2): 25
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489945/
■ Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer
Catherine M. Phelan, Karoline B. Kuchenbaecker et al
Nat Genet.2017, vol49(5): 680–691.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612337/
■ The unique molecular and cellular microenvironment of ovarian cancer
Thomas Worzfeld, ElkePogge von Strandmann, Magdalena Huber et al
Front Oncol.2017;vol7: 24
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319992/
■ Management of relapsed ovarian cancer: a review
G H Giomelli
Springerplus 2016, vol 5 (1): 1197
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963348/
■ Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: a review
Eric R. Craig, Angelina I. Londoño, Lyse A. Norian, Rebecca C. Arend
GynecolOncol. 2016 Dec; 143(3): 674–683
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689410/
■ Mechanisms and target involved in dissemination of ovarian cancer
U H Weidle, F Birzele, G Kollmorgen, R Rueger
CancerGenomics Proteomics.2016 Nov-Dec; 13(6): 407–423.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219915/
■ Ovarian cancer screening and mortality in the UK Collaborative Trial of ovarian cancer screening (UKCTOCS): a randomized controlled trial
I J Jacobs, U Menon, A Ryan et al
Lancet 2016, vol 387 (10022): 945-956
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779792/
■ Ovarian cancer screening and mortality in the UK Collaborative Trial of ovarian cancer screening (UKCTOCS): a randomized controlled trial
I J Jacobs, U Menon, A Ryan et al
Lancet 2016, vol 387 (10022): 945-956
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779792/
■ The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patient with ovarian cancer
Emmanouil V. Dermitzakis, Vasilios K. Kimiskidis, George Lazaridis et al
BMC Neurol.2016; vol16: 19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045633/
■ Racial/ethnic differences affecting adherence to cancer screening guidelines among women
Jacqueline M. Hirth, TabassumHaque Laz, Mahbubur Rahman, Abbey B. Berenson
J Womens Health (Larchmt) 2016, vol25(4): 371–380
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505474/
■ Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment
Veronica Rojas, Kim M. Hirshfield, ShridarGanesan, Lorna Rodriguez-Rodriguez
Int J Mol Sci.2016, vol17(12): 2113
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187913/
■ Maintaining sexual health throughout gynecologic cancer survivorship: a comprehensive review and clinical guide
Laura B. Huffman, Ellen M. Hartenbach, Jeanne Carter et al
GynecolOncol. 2016, vol140(2): 359–368
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835814/
■ How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer
Sharon L. Bober, Jennifer B. Reese, Lisa Barbera et al
CurrOpin Support Palliat Care. 2016 Mar; 10(1): 44–54.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984532/
■ Adherence of primary care physician to evidence-based recommendations to reduce ovarian cancer mortality
Sherri L. Stewart, Julie S. Townsend, Mary C. Puckett, Sun Hee Rim
J Womens Health (Larchmt). 2016, vol25(3): 235–241.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289707/
■ Management, prognosis and reproductive outcomes of borderline ovarian tumor relapse during pregnancy: from diagnosis to potential treatment options
Francesco Cosentino, Luigi Carlo Turco, Stefano Cianciet al
J Prenat Med.2016, vol10(1-2): 8–14
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505474/
■ Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2014-to 2011
Sagar C. Patel, Jonathan Frandsen, Sudershan Bhatia, David Gaffney
J GynecolOncol.2016, vol27(5): e45
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944012/
■ Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian fallopian tube, and primary peritoneal cancers
Jovana Y. Martin, Renata R. Urban, John B. Liao, Barbara A. Goff
J GynecolOncol.2016, vol 27(5): e47.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944014/
■ Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer
Tiffany Lai, Bruce Kessel, Hyeong Jun Ahn, Keith Y. Terada
J GynecolOncol.2016 Jul; vol27(4): e41
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864517/
■ Differences in risk for type 1 and type 2 ovarian câncer in a large câncer screening trial
Keith Y. Terada, Hyeong Jun Ahn, Bruce Kessel
J GynecolOncol.2016 May; 27(3): e25
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823356/
■ Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
Brittney S Harrington, Yaowu He, Claire M Davies et al
Br J Cancer.2016, vol114(4): 417–426
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815773/
■ Adult body mass index and risk of ovarian cancer subtype: a Mendelian randomization study
Suzanne C Dixon, Christina M Nagle, Aaron P Thrift et al
on behalf of the Ovarian CancerAssociation Consortium,
AOCS Group & Australian CancerStudy (Ovarian Cancer)
Int J Epidemiol.2016 Jun; vol45(3): 884–895
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644573/
■ Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study
Katrijn L M Michielsen, IgnaceVergote, RaphaëlaDresen et al
Br J Radiol. November 2016; 89(1067): 2016046
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124845/
■ Analgesic medications use and risk of epithelial ovarian cancer in African American women
Lauren C Peres, Fabian Camacho, Sarah E Abbott et al
Br J Cancer. 2016 Mar 29; 114(7): 819–825
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984862/
■ Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Jue-Sheng Ong, Gabriel Cuellar-Partida, Yi Lu et al
Australian Ovarian Cancer Study
Int J Epidemiol. 2016 Oct; vol45(5): 1619–1630
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100621/
■ Mature Cystic Teratoma of Ovary with Abnormally High Levels of Ca19-9: A Case Report
Sampaio, Joana et al.
Rev. Bras. Ginecol. Obstet., July 2016, vol.38, no.7, p.365-367
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032016000700365&lng=pt&nrm=iso
■ SIADH secundario a adenocarcinoma seroso de ovario tratado conTolvaptán
Araujo Castro, Marta et al.
Rev. chil. obstet. ginecol.,Dic 2016, vol.81, no.6, p.507-510
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262016000600009&lng=en&nrm=iso
■ Tuberculosis peritoneal conpresentación clínica como cáncer ovárico avanzado: revisión de la literatura
Serman V, Felipe et al.
Rev. chil. obstet. ginecol., 2016, vol.81, no.5, p.411-42
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262016000500011&lng=en&nrm=iso
■ Dolor abdominal agudo como presentación de un linfoma ovárico.
LafallaBernad, Olivia et al.
Rev. chil. obstet. ginecol., 2016, vol.81, no.5, p.399-405.
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262016000500009&lng=en&nrm=iso
■ United Kingdom Collaborative Trial of Ovarian Cancer Screening
U Menon, A Ryan, J Kalsi et al
Journal of Clinical Oncology jun 2015
http://ascopubs.org/doi/full/10.1200/JCO.2014.59.4945
■ Asociación entre obesidad y cáncer de ovário
Valladares, Macarena, Corsini, Gino and Romero, Carmen
Rev. méd. Chile, Mayo 2014, vol.142, no.5, p.593-59
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000500007
■ Risk assessment, genetic counseling and genetic testing for BRCA-related cancer in women
- S. Preventive Services Task Force Recommendation Statement
V A Moyer
Ann Intern Med 2014, vol 160 (4): 271-281
■ Screening for ovarian cancer
- S. Preventive Services Task Force Recommendation Statement
V A Moyer
Ann Intern Med 2012, vol 157 (12): 900-904
■ Manejo multidisciplinar delcáncer epitelial de ovario: Diagnóstico radiológico.
Sánchez, M.C., Sáenz, J. andOstiz, S.
AnalesSis San Navarra, Ago 2011, vol.34, no.2, p.275-28
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272011000200013&lng=en&nrm=iso
■ byDr Paulo Fernando Leite
Cardiologia – Centro Médico Unimed BH
Rua Gonçalves Dias 202
Belo Horizonte/MG/Brasil
31 30033306/40204020
CRMMG: 7026
Email: pfleite1873@gmail.com